Citigroup Downgrades Bio-Techne to Neutral, Announces $85 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Patrick Donnelly has downgraded Bio-Techne (NASDAQ:TECH) from Buy to Neutral and set a price target of $85.

May 22, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup analyst Patrick Donnelly downgraded Bio-Techne from Buy to Neutral and set a price target of $85.
The downgrade from Buy to Neutral by a major financial institution like Citigroup is likely to negatively impact investor sentiment and could lead to a short-term decline in Bio-Techne's stock price. The new price target of $85 suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100